Avalon, GSK fund two more startups under collaboration
This article was originally published in Scrip
Avalon Ventures and GlaxoSmithKline have launched Silarus Therapeutics and Thyritope Biosciences, the second and third San Diego-based biotechnology companies formed under a partnership that Avalon and GSK initiated in 2013 to fund up to 10 new startup firms.
You may also be interested in...
Celiac disease specialist Sitari was the first company formed under the six-year collaboration. Three were shut down and Avalon controls the other four, which aren't compatible with GSK's new R&D focus.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.